How big is Precision BioSciences, Inc.?

As of Jun 18, Precision BioSciences, Inc. has a market capitalization of 58.30 million and reported net sales of 51.15 million with a net loss of 22.00 million over the latest four quarters. The balance sheet shows shareholder's funds of 56.39 million and total assets of 136.39 million.

As of Jun 18, Precision BioSciences, Inc. has a market capitalization of 58.30 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 51.15 million for the latest four quarters, while the net profit for the same period was a loss of 22.00 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 56.39 million and total assets of 136.39 million.

What does Precision BioSciences, Inc. do?

Precision BioSciences, Inc. is a genome editing company in the Pharmaceuticals & Biotechnology sector, currently reporting no net sales and a net loss of $21 million as of March 2025, with a market cap of $58.30 million. The company has a negative debt-equity ratio and return on equity, with no dividend yield.

Overview: <BR>Precision BioSciences, Inc. is a genome editing company engaged in providing genome engineering technology within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 58.30 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.08 <BR>Return on Equity: -83.23% <BR>Price to Book: 1.18<BR><BR>Contact Details: <BR>Address: 302 E Pettigrew St Ste A100, DURHAM NC: 27701-2393 <BR>Tel: 1 919 3145512 <BR>Website: http://precisionbiosciences.com/

Should I buy, sell or hold Precision BioSciences, Inc.?

Who are in the management team of Precision BioSciences, Inc.?

As of March 2022, the management team of Precision BioSciences, Inc. includes President and CEO Matthew Kane and Chief Scientific Officer Derek Jantz, along with independent directors Kevin Buehler, Geno Germano, Raymond Schinazi, Shalini Sharp, and Tony Yao. They oversee the company's strategic direction and scientific advancements.

As of March 2022, the management team of Precision BioSciences, Inc. includes the following individuals:<BR><BR>- Mr. Matthew Kane: President, Chief Executive Officer, and Director<BR>- Mr. Derek Jantz: Chief Scientific Officer and Director<BR><BR>Additionally, the board of directors features several independent directors:<BR><BR>- Mr. Kevin Buehler<BR>- Mr. Geno Germano<BR>- Mr. Raymond Schinazi<BR>- Ms. Shalini Sharp<BR>- Dr. Tony Yao<BR><BR>This team is responsible for guiding the company's strategic direction and scientific advancements.

Is Precision BioSciences, Inc. overvalued or undervalued?

As of May 15, 2025, Precision BioSciences, Inc. is considered risky and overvalued due to poor financial metrics and a one-year stock performance of -48.85%, significantly underperforming the S&P 500's 17.14% return.

As of 15 May 2025, the valuation grade for Precision BioSciences, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.32, an EV to EBITDA of -0.29, and a ROE of -83.23%. Compared to peers, ImmunoPrecise Antibodies Ltd. has a significantly higher P/E ratio of -13.04, while Marker Therapeutics, Inc. shows a similar risk profile with an EV to EBITDA of 0.0342.<BR><BR>In terms of stock performance, Precision BioSciences has underperformed relative to the S&P 500, with a one-year return of -48.85% compared to the index's 17.14%. This stark contrast reinforces the notion that the stock is overvalued in its current state.

Is Precision BioSciences, Inc. technically bullish or bearish?

As of August 21, 2025, Precision BioSciences, Inc. shows a mixed technical stance leaning mildly bearish, with positive momentum in MACD indicators but underperformance compared to the S&P 500, having a year-to-date return of 28.87% and a decline of 48.85% over the past year.

As of 21 August 2025, the technical trend for Precision BioSciences, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a sideways trend on the weekly chart and mildly bearish on the monthly chart. The KST indicates a mildly bullish stance weekly but bearish monthly, and the OBV is mildly bearish weekly while bullish monthly. Overall, the indicators suggest a mixed technical stance leaning towards mildly bearish.<BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 28.87% versus the S&P 500's 12.22%, but a significant decline of 48.85% over the past year compared to the S&P 500's 17.14%.